Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2018

At a glance

  • Drugs BPN 14770 (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions
  • Sponsors Tetra Discovery Partners
  • Most Recent Events

    • 18 Dec 2018 According to a Tetra Discovery Partners media release, the company has entered into a strategic collaboration with Shionogi for the clinical development and commercialization of BPN14770 (FXS, Alzheimers disease, other indications: cognitive and memory deficits).In exchange for granting Shionogi development rights to BPN14770 in Japan, Taiwan and Korea, Tetra has received 40 million dollar in combined upfront funding.This new funding will enable Tetra to complete this study.
    • 10 Jul 2018 According to a Tetra Discovery Partners media release, this trial is being conducted with financial support from the FRAXA Research Foundation.
    • 27 Jun 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top